Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.86 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036152 | 0.93 | EGFR (1.00) | EGFRKDRSRC | |
| SCHEMBL4031397 | 0.92 | EGFR (0.73) | EGFRKDRSRCEPHA2EPHB4 | |
| SCHEMBL4036214 | 0.92 | EGFR (0.83) | EGFRKDRSRC | |
| SCHEMBL4037175 | 0.91 | EGFR (0.72) | EGFRKDRSRCEPHA2EPHB4 | |
| SCHEMBL4040826 | 0.91 | EGFR (0.72) | EGFRKDRSRC | |
| SCHEMBL4033136 | 0.89 | EGFR (0.91) | EGFRKDRSRC | |
| SCHEMBL4034245 | 0.87 | EGFR (0.67) | EGFRKDRSRC | |
| SCHEMBL4040011 | 0.87 | EGFR (0.81) | EGFRKDRSRCEPHA2EPHB4 | |
| SCHEMBL4218564 | 0.87 | EGFR (0.71) | EGFRKDRSRC | |
| SCHEMBL4032117 | 0.87 | EGFR (0.78) | EGFRKDRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| CN-1764651-A | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2006-04-26 | — | — | CN | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | EGFR 4/4885KDR 75/4885SRC 111/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | EGFR 2/4885KDR 33/4885SRC 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.